ClinicalTrials.gg
Not yet recruitingNCT07338071PEACEUpdated Jan 13, 2026

Antithrombotic Therapy at the End of Life: The PEACE Study

An observational study in Palliative Care, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Not yet recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
410
Ages
18 Years and older
Sex
All
01

Study summary

"Antithrombotic Therapy at the End of Life: The PEACE Study" is a multicenter, non-profit, cross-sectional observational study. In the absence of shared guidelines, therapeutic decisions on antithrombotic drugs vary significantly according to healthcare professional training and national context, resulting in marked variability in prescribing practices. This study aims to describe the prevalence of antithrombotic prescriptions in patients referred to Palliative Care.

02

Conditions studied

  • Palliative Care

Browse trials for

Keywords

  • antithrombotic therapy
  • end of life
  • palliative care
03

In context

Death

456 studies on the registry are indexed under Death; 86 are open to participants now.

This study's planned enrollment of 410 is close to the median of 400 across 236 observational studies indexed under Death.

Browse Death studies →

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 952 studies on the registry; 541 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study sample will consist of hospitalized patients referred to a Palliative Care pathway

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥18 years) hospitalized and referred to Palliative Care (home-based or residential) at the discretion of the attending physician.
  • Signed

Exclusion criteria

Exclusion Criteria:

  • none
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
410 participants (estimated)
Patient registry
No

Interventions

  • Drugantithrombotic drugs

    use of antithrombotic drug

06

What researchers measure

Primary outcomes

  1. Prevalence of antithrombotic drug use

    Calculation of the prevalence of antithrombotic drug use in hospitalized patients referred to Palliative Care pathway.

    Time frame: at enrollment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07338071
Collaborators
Ospedale Cristo Re - Roma, San Giovanni Addolorata Hospital
Responsible party
Pola Roberto (Prof., Fondazione Policlinico Universitario Agostino Gemelli IRCCS) — Principal investigator
First posted
Jan 13, 2026
Start date
Jan 2026 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jan 13, 2026

Study contacts

Roberto Pola
Contact
roberto.pola@policlinicogemelli.it
+390630157075
Rosa Talerico
Contact
rosa.talerico@unicatt.it
+390630157075

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion